Thyroid replacement therapy effects on cardiac function in patients with hypothyroidism

Aleksandar Đenić1, Biljana Obrenović-Kirčanski2,3
1Zlatibor Special Hospital for thyroid gland and metabolism diseases, Zlatibor, Serbia;
2University of Belgrade, Faculty of Medicine, Belgrade, Serbia;
3Clinical Centre of Serbia, Cardiology Clinic, Belgrade, Serbia

SUMMARY
Introduction/Objective Hypothyroidism is a hypometabolic syndrome with insufficient production or inadequate action of thyroid hormones. It is characterized by hypercholesterolemia, elevated LDL-C. The most common echocardiographic changes are in left ventricular (LV) diastolic function. The aim of this study was to investigate the effects of achieving adequate thyroid hormone replacement therapy in hypothyroid patients on improving systolic and diastolic cardiac function and correcting serum lipid profile.

Methods Prospective study was conducted on 42 patients with newly diagnosed hypothyroidism, both sexes, aged 18–60 years, without comorbidity. The determined blood tests before, six, 12, and 24 weeks after starting the therapy with L-thyroxine were: FT4, TSH, total cholesterol, HDL-C, LDL-C and triglycerides. The effects of thyroid hormone replacement therapy on systolic and diastolic cardiac function were assessed by echocardiography.

Results It was concluded that 25 (59.5%) patients had subclinical and 17 (40.5%) overt hypothyroidism. The LV end-systolic diameter decreased statistically highly significant (p < 0.01) after 12 weeks and end-diastolic diameter of the right ventricle after six months of therapy. There was no significant decrease in LV end-diastolic diameter after six months of thyroid hormone replacement therapy. Mitral annular plane systolic excursion (MAPSE), left ventricular ejection fraction (LVEF), and tricuspid annular plane systolic excursion (TAPSE) values increased significantly (p < 0.01) after six weeks of therapy. Total cholesterol and LDL-C significantly decreased, HDL-C increased (p < 0.01) and there was no change in triglyceride concentrations after 24 weeks of therapy.

Conclusions Thyroid replacement therapy in hypothyroid subjects statistically significantly improves echocardiographic parameters of diastolic and systolic left and right ventricular function, reduces total serum cholesterol and LDL-C, and increases HDL-C.

Keywords: hypothyroidism; L-thyroxine; diastolic cardiac function; systolic cardiac function; lipid profile

INTRODUCTION
Thyroid hormone deficiency leads to changes in cardiovascular hemodynamics, phenotype and contractility, and accelerated atherosclerosis. Overt hypothyroidism exerts effects on systolic and diastolic cardiac function and cardiac anatomy [1, 2].

Hypothyroidism increases the risk of developing atherosclerotic cardiovascular disease by increasing circulating LDL cholesterol (LDL-C) levels, inducing the development of diastolic hypertension, increasing blood coagulability, as well as having direct effects on vascular smooth muscle. Overt hypothyroidism is characterized by hypercholesterolemia, significantly elevated LDL-C and apolipoprotein B [3].

In subclinical hypothyroidism, diastolic cardiac function is most commonly impaired, which is already manifested in patients with mild thyroid dysfunction with TSH between 5 and 10 mU/L [4]. Subclinical hypothyroidism is associated with a small increase in LDL cholesterol (LDL-C), a decrease in HDL cholesterol (HDL-C), increasing the risk of developing atherosclerosis and coronary artery disease [5].

The most common echocardiographic changes in hypothyroidism are characterized by changes in left ventricular (LV) diastolic function parameters resulting from impaired myocardial relaxation presented by prolonged isovolumic relaxation time (IVRT) and a significantly reduced early and late diastolic flow rate (E/A) of mitral flow. Echocardiographic diastolic dysfunction is defined by the existence of at least one of the following parameters: E/A < 1.0, IVRT > 100 m/s, or decelerating time > 220 m/s [6].

The interaction between the right and left ventricles is one of the most important causes of impaired right ventricular function that results from an increase in LV filling pressure and the consequent increase in pulmonary flow and pressure in the right ventricle. It has been shown that impaired right ventricular mechanics are completely repaired after adequate thyroid hormone replacement therapy [7].

The aim of this study was to examine the effects of achieving adequate thyroid hormone replacement therapy in hypothyroid patients on:
METHODS

A prospective study was conducted on 42 patients over a 24-week follow-up period. The study was performed from September 2017 until March 2019 at the Zlatibor Special Hospital for Thyroid gland and Metabolic Diseases. The study was approved by the Ethics Committee and all study participants were informed of the study methodology and gave their consent to participate in the study.

The study included patients with newly diagnosed hypothyroidism whose TSH was greater than 10 mU/L, both sexes, aged 18–60 years, without comorbidity. Echocardiographic examinations were determined by transthoracic echocardiography on a Vivid 3 apparatus (GE Healthcare, Solingen, Germany). The systolic function was determined by the following echocardiographic parameters: LV ejection fraction (LVEF), mitral annular plane systolic excursion (MAPSE) and tricuspid annular plane systolic excursion (TAPSE). Diastolic function was determined by the following echocardiographic parameters: E wave (m/s), A wave (m/s), E/A ratio, IVRT of the left ventricle (ms). The left and right ventricular systolic function parameters were measured using the M-mode in the parasternal long-axis view and the apical 4-chamber view. The LVEF, expressed in %, was determined by a Teicholtz formula calculation. Transmitral flow rates were measured using a pulsed Doppler in the apical four chamber view. Using a continuous Doppler in the apical five-chamber view, IVRT was determined. Echocardiographic parameters were assessed before and after received L-thyroxine therapy at weeks six, 12, and 24.

The following laboratory parameters were determined from the blood: total cholesterol (TC), cholesterol fractions HDL and LDL, and triglycerides. Thyroid function was assessed by measuring free-thyroxine (FT4) and thyrotropin (TSH) levels. After determining basal FT4 and TSH levels, patients with TSH greater than 10 mU/L included in the study were administered L-thyroxine with a gradual increase in dose until euthyroid condition was achieved. Lipid status and thyroid function were assessed before and after received L-thyroxine therapy at weeks six, 12, and 24.

Descriptive and analytical statistical methods were used in this study. Descriptive methods used absolute and relative numbers, measures of central tendency (arithmetic means, median) and dispersion measures (standard deviation).

Analytical statistical methods used difference tests, parametric and non-parametric tests. The selected level of significance, that is, the probability of an error of the first type is 0.05. All data were processed in IBM SPSS Statistics, Version 20.0. (IBM Corp., Armonk, NY, USA) software package.

RESULTS

Of the 42 respondents included in the study, 9 (21.4%) were male and 33 (78.6%) were female. The mean age of studied patients was 40.1 ± 9.1 years. The youngest patient was 19 years old and the oldest was 59 years old. The mean BMI values were 24.67 ± 2.81 kg/m².

Of the 42 subjects enrolled, 25 (59.5%) had a subclinical form of hypothyroidism and 17 (40.5%) had an overt form of hypothyroidism.

FT4 before starting the therapy was 10.82 ± 3.19 pmol/L, in the repeated measurements after six, 12 and 12 weeks were in the range of reference (10.2–24.5 pmol/L) for all subjects (Table 1) and after 24 weeks were 16.23 ± 3.77 pmol/L indicating a statistically highly significant difference (p < 0.01). Out of the 42 enrolled subjects, 34 achieved TSH in reference range (0.3–4.2 mU/L) after 24 weeks of therapy while 8 did not. Out of the eight subjects with inadequate TSH values (greater than 4.2 mU/L), five patients had slightly elevated TSH values above the reference range (up to 6 mU/L) and only one subject had a TSH value greater than 10 mU/L. There was a statistically significant difference in the TSH value after six and 12 weeks (p < 0.05) and a highly statistically significant difference in the TSH value after 24 weeks of thyroid replacement therapy (p < 0.01) compared to the initial TSH values.

Table 1. Thyroid hormone values in the function of time (n = 42)

| Parameter | Before therapy (I) | Six weeks later (II) | 12 weeks later (III) | 24 weeks later (IV) |
|-----------|--------------------|----------------------|----------------------|---------------------|
| FT4 (pmol/L) | 10.82 ± 3.19 | 15.34 ± 2.74 | 15.85 ± 3.81 | 16.23 ± 3.77 |
| TSH (mU/L) | min–max | min–max | min–max | min–max |

FT4 – free-thyroxine; TSH – thyrotropin

Hypothyroid subjects had a statistically highly significant (p < 0.01) increase in E wave velocity and increase in the 12th week of L-thyroxine therapy.

The results of LV systolic function are presented in Table 2. There was no statistically significant decrease in LV end-diastolic diameter (LVEDD) after 24 weeks of therapy (p > 0.05), whereas end-systolic LV diameter (LVESD) decreased statistically highly significant (p < 0.01) from the initial value of 4.2 mU/L

MAPSE and LVEF were statistically significant (p < 0.01) improved after six, 12 and 24 weeks of therapy, significant improvement in LV function after beginning of thyroid hormone therapy (Table 2).

RESULTS

Hypothyroid subjects had a statistically highly significant (p < 0.01) increase in E wave velocity and increase in the 12th week of L-thyroxine therapy.

The results of LV systolic function are presented in Table 2. There was no statistically significant decrease in LV end-diastolic diameter (LVEDD) after 24 weeks of therapy (p > 0.05), whereas end-systolic LV diameter (LVESD) decreased statistically highly significant (p < 0.01) from the initial value of 4.2 mU/L

MAPSE and LVEF were statistically significant (p < 0.01) improved after six, 12 and 24 weeks of therapy, significant improvement in LV function after beginning of thyroid hormone therapy (Table 2).
Table 2. Left ventricular size and systolic function parameters

| Parameter     | Before therapy (I) | Six weeks later (II) | 12 weeks later (III) | 24 weeks later (IV) |
|---------------|--------------------|----------------------|----------------------|---------------------|
| LVEDD (mm)    | 49.07 ± 3.70       | 49.02 ± 3.83         | 48.64 ± 3.45         | 48.48 ± 3.58        |
| LVESD (mm)    | 31.02 ± 2.99       | 30.45 ± 3.39         | 29.21 ± 3.35         | 27.67 ± 2.82        |
| MAPSE (mm)    | 14.52 ± 1.42       | 15.21 ± 1.37         | 16.24 ± 1.62         | 16.81 ± 1.67        |
| LVEF (%)      | 65.19 ± 3.57       | 66.52 ± 3.74         | 69.09 ± 3.77         | 72.45 ± 3.55        |

LVEDD – left ventricular end-diastolic diameter; LVESD – left ventricular end-systolic diameter; MAPSE – mitral annular plane systolic excursion; LVEF – left ventricular ejection fraction

Table 3. Left ventricular diastolic function parameters

| Parameter | Before therapy (I) | Six weeks later (II) | 12 weeks later (III) | 24 weeks later (IV) |
|-----------|--------------------|----------------------|----------------------|---------------------|
| E (m/s)   | 0.71 ± 0.14        | 0.74 ± 0.12          | 0.77 ± 0.11          | 0.80 ± 0.11         |
| A (m/s)   | 0.76 ± 0.12        | 0.72 ± 0.12          | 0.66 ± 0.1           | 0.61 ± 0.11         |
| E/A       | 0.94 ± 0.13        | 1.04 ± 0.14          | 1.19 ± 0.17          | 1.32 ± 0.19         |
| IVRT (ms) | 102.59 ± 8.43      | 94.54 ± 8.76         | 87.59 ± 8.14         | 80 ± 7.29           |

E wave – early diastolic velocity of transmitral flow; A wave – late diastolic velocity of transmitral flow; E/A – a ratio of early and late diastolic velocity of transmitral flow; IVRT – isovolumic relaxation time of the left ventricle

Table 4. Parameters of right ventricular size and systolic function

| Parameter | Before therapy (I) | Six weeks later (II) | 12 weeks later (III) | 24 weeks later (IV) |
|-----------|--------------------|----------------------|----------------------|---------------------|
| RV (mm)   | 24.79 ± 1.93       | 24.69 ± 2.02         | 24.36 ± 2.18         | 24.24 ± 2.13        |
| TAPSE (mm)| 19.88 ± 1.63       | 20.88 ± 1.74         | 21.78 ± 1.6          | 22.52 ± 1.61        |

RV – right ventricular end-diastolic diameter; TAPSE – tricuspid annular plane systolic excursion

Table 5. Blood lipid values as a function of measurement time

| Parameter      | Before therapy (I) | Six weeks later (II) | 12 weeks later (III) | 24 weeks later (IV) |
|----------------|--------------------|----------------------|----------------------|---------------------|
| TC (mmol/L)    | 6.00 ± 1.27        | 5.32 ± 0.84          | 5.49 ± 1.05          | 5.23 ± 0.87         |
| HDL-C (mmol/L) | 1.26 ± 0.20        | 1.36 ± 0.29          | 1.37 ± 0.29          | 1.40 ± 0.26         |
| LDL-C (mmol/L) | 3.94 ± 0.97        | 3.31 ± 0.74          | 3.45 ± 0.88          | 3.25 ± 0.78         |
| TG (mmol/L)    | 0.50–5.94          | 0.54–4.69            | 0.40–5.25            | 0.39–3.00           |

TC – plasma total cholesterol; HDL-C – high-density lipoprotein-associated cholesterol; LDL-C – low-density lipoprotein-associated cholesterol; TG – triglycerides

There was a highly statistically significant increase (p < 0.01) in TAPSE values six, 12 and 24 weeks after initiation of L-thyroxine therapy. No statistically significant difference was found in successive measurements of right ventricular (RV) end-diastolic diameter after six and 12 weeks of therapy, as well as successive measurements between the 12th and the 24th week (p > 0.05), and the difference was highly statistically significant (p < 0.01) at the end of the 24th week of therapy relative to baseline right ventricular diameter values - prior to initiation of therapy (Table 4).

DISCUSSION

The prevalence of subclinical hypothyroidism (elevated serum TSH and normal FT4) is 8% in women (10% in women over 55 years) and 3% in men (UK Whickham cohort study) [8]. In our study, the distribution with a higher prevalence of a subclinical hypothyroidism (in 25 subjects – 59.5%) also corresponds to its higher prevalence in transmirtal flow ratio (E/A), whereas the decrease in A wave velocity was a statistically highly significant (p < 0.01) after six, 12 and 24 weeks of therapy (Table 3). There was a trend of increasing the rate of E/A in successive measurements during L-thyroxine therapy.

The isovolumic LV relaxation time (IVRT) was highly statistically significant (p < 0.01) after six and 24 weeks of therapy, whereas the difference was not statistically significant (p > 0.05) in successive measurements of IVRT between six and 12 weeks, as well as between 12 and 24 weeks of therapy (Table 3). There was a constant decrease in IVRT during successive measurements after the beginning of L-thyroxine therapy.

Results of the right cardiac function parameters

There was a highly statistically significant increase (p < 0.01) in TAPSE values six, 12 and 24 weeks after initiation of L-thyroxine therapy. No statistically significant difference was found in successive measurements of right ventricular (RV) end-diastolic diameter after six and 12 weeks of therapy, as well as successive measurements in serum concentrations of total cholesterol, HDL-C and LDL-C were statistically highly significant decreased (p < 0.01), whereas serum levels of HDL-C were highly statistically significant (p < 0.01) increased after six and 24 weeks of therapy. There was no statistically significant difference (p > 0.05) in the measured serum concentrations of total cholesterol, HDL-C and LDL-C between sixth and 12th week and 12th and 24th week of therapy (Table 5).

The trend line of mean values of serum lipid concentrations (total cholesterol, HDL-C and LDL-C) in successive measurements (Figure 1) showed an increase in HDL-C which was observed after the beginning of thyroid replacement therapy. The trend lines for total cholesterol and LDL-C showed a decrease in serum concentrations after six weeks of therapy, with an unexpected increase in serum concentrations of total cholesterol and LDL-C after 12 weeks. After 24 weeks the serum levels of total cholesterol and LDL-C were lower in relation to values before the starting L-thyroxine therapy.
L-thyroxine therapy leads to an improvement of right ventricular function. Some studies have shown an association between clinical hypothyroidism and right ventricular diastolic dysfunction, as well as an increase in right ventricular wall thickness. A number of studies have shown that damaged right ventricular mechanics are completely repaired after adequate thyroid hormone dose [18, 19].

The thyroid replacement therapy in hypothyroid subjects significantly improves the echocardiographic parameters of LV diastolic function, especially after three months of L-thyroxine therapy with an average transmitral flow rate E/A > 1.0 (1.1 ± 0.17) and IVRT < 100 m/s (87.59 ± 8.14 m/s). The use of L-thyroxine significantly improves the echocardiographic parameters of LV systolic function (LVEF, MAPSE). After six months of therapy there was no significant change in the diastolic diameter of the left ventricle. L-thyroxine therapy also improves the right ventricular systolic function. In our study, improvements of the parameters of left and right ventricular systolic and diastolic function after the administration of L-thyroxine were expected and consistent with the reported study results.

The increased prevalence of the atherosclerotic cardiovascular disease in subclinical hypothyroidism was demonstrated in a Rotterdam study, which showed that middle-aged women with subclinical hypothyroidism (with TSH greater than 4 mU/L) had a higher prevalence of coronary artery disease than the control sample with TSH less than 4 mU/L [20].

Increased serum concentrations of LDL cholesterol, triglycerides, apolipoprotein B and increased LDL oxidation might explain the association between subclinical hypothyroidism and cardiovascular disease. This pattern of serum atherogenic profile is more pronounced in patients with serum TSH levels greater than 10 mU/L and in smokers. A meta-analysis of 55,287 patients from 11 prospective cohort studies showed that subclinical hypothyroidism in patients with higher TSH levels were associated with higher mortality and prevalence of coronary diseases [21].

Studies have shown that increase in serum TSH levels by 1 mU/L increased total serum cholesterol by 0.09 mmol/L in women and by 0.16 mmol/L in men [22]. A meta-analysis of studies that monitored the effects of levothyroxine therapy on lipid profile in subclinical hypothyroidism showed that serum total cholesterol decreased by about 0.2 mmol/L or serum LDL cholesterol by about 0.3 mmol/L after L-thyroxine therapy, while triglycerides and HDL-C remained unchanged [23]. McGowan et al. [24] have shown a significant increase in HDL cholesterol by normalizing serum TSH concentrations by levothyroxine therapy.

In our study thyroid replacement therapy had been shown to reduce serum total cholesterol and LDL-C concentrations, increase HDL-C, and no significant effects...
on serum triglyceride concentrations. The effects of L-thyroxine therapy on the parameters of the lipid profile in the subjects described in our study indicate consistent and expected results, as shown in the studies cited by other authors. The paradoxical and unexpected increase in total cholesterol and LDL-C after 12 weeks of therapy could be explained by the uncontrolled conditions of the trial, i.e., inability to control the dietary regime of the subjects in addition to the advice given at the controls, as well as fluctuations of thyroid hormones (FT4 and TSH), which is a characteristic at the beginning (in the first three months) of the use of levothyroxine therapy.

CONCLUSIONS

Thyroid replacement therapy in hypothyroid subjects significantly improves the echocardiographic parameters of LV diastolic function, especially after the third month of initiation of therapy. Administration of L-thyroxine leads to a significant improvement in left and right ventricular systolic parameters. Levothyroxine therapy significantly reduced the risk factors for the development of atherosclerosis and coronary artery disease: reduction of total serum cholesterol and LDL-C, and increase of HDL-C.

Conflict of interest: None declared.

REFERENCES

1. Udovcic M, Pena RH, Patham B, Tabatabai L, Kansara A. Hypothyroidism and the heart. Methodist Debakey Cardiovasc J. 2017;13(2):55–9.
2. Tafarshiku R, Henein MY, Berisha-Muharem V, Bytyci I, Ibrahim I, Poniku A, et al. Left ventricular diastolic and systolic functions in patients with hypothyroidism. Medicina. 2020;56(10):524.
3. Razvi S, Jabbar A, Pingitore A, Danzi S, Biondi B, Klein I, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71(16):1781–96.
4. Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019;322(1):153–60.
5. Delitala AP, Fanciulli G, Maolli M, Delitala G. Subclinical hypothyroidism, lipid metabolism and cardiovascular disease. Eur J Intern Med. 2017;38:17–24.
6. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2016;29(4):277–314.
7. Klein I, Danzi S. Thyroid disease and the heart. Curr Probl Cardiol. 2016;41(2):65–92.
8. Hennessey JV, Espaillat R. Subclinical hypothyroidism: a historical view and shifting prevalence. Int J Clin Pract. 2015;69(7):771–82.
9. Stott DJ, Rodondi N, Kearney PM. TRUST Study Group. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71(16):1781–96.
10. McAninch EA, Bianco AC. New insights into the variable role of echocardiography in monitoring the therapeutic effect of levothyroxine replacement therapy in subclinical hypothyroidism. Arch Biol Sci. 2020;72(1):137–46.
11. Gholami R, Kalbsai S, Sheibani M, Davoudi Z, Sadeghi R, Meeckunickee F, et al. Efficacy of Levothyroxine Therapy on Diastolic Dysfunction in Patients with Subclinical Hypothyroidism. Novelty in Byomedicine. 2020;8(1):31–5.
12. Tadic M, Ilic S, Celic V. Right ventricular and right atrial function and deformation in patients with subclinical hypothyroidism: a two- and three-dimensional echocardiographic study. Eur J Endocrinol. 2013;170(1):77–85.
13. Vargas-Uricochea H, Bonelo-Perdomo A. Thyroid dysfunction and heart failure: mechanisms and associations. Curr Heart Fail Rep. 2017;14(1):48–58.
14. Bano A, Chaker L, Mattace-Raso FU, Van der Lugt A, Ikram MA, Franco OH, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: the Rotterdam Study. Circ Res. 2017;121(12):1392–400.
15. Biondi B. Persistent dyslipidemia in patients with hypothyroidism: a good marker for personalized replacement therapy? J Clin Endocrinol Metab. 2019;104(2):624–62.
16. Jain RB. Associations between the levels of thyroid hormones and lipid/lipoprotein levels: data from National Health and Nutrition Examination Survey 2007–2012. Environ Toxicol Pharmacol. 2017;53:133–44.
17. Li X, Wang Y, Guan Q, Zhao J, Gao L. The lipid-lowering effect of levothyroxine in patients with subclinical hypothyroidism: a systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol. 2017;87(1):1–9.
18. McGowan A, Widdowson WM, O’Regan A, Young IS, Boran G, McEneny J, et al. Postprandial studies uncover differing effects on HDL particles of overt and subclinical hypothyroidism. Thyroid. 2016;26(3):356–64.
САЖЕТАК
Увод/Циљ Хипотиреоидизам је синдром хипометаболизма са недовољном производњом или неадекватним дејством тиреоидних хормона. Карактерише се хиперхолестеролемијом, повишеним ЛДЛ-холестеролом, а најчешћа ехокардиографска промена је поремећај параметара дијастолне функције леве срчане коморе.

Циљ истраживања је испитивање утицаја постизане адекватне супституције тироидним хормонима код хипотиреоидних болесника на побољшање систолне и дијастолне функције срца и кориговање липидног профилу у серуму.

Методе Спроведена је проспективна студија на 42 болесника са новооткривеном хипотиреозом, оба пола, узраста 18–60 година, без коморбидитета. Одређиване су вредности ФТ4, ТСХ, укупног холестерола, ХДЛ-Х, ЛДЛ-Х и триглицериде пре започињања, шест, 12 и 24 недеље после терапије Л-тироксином. Утицај супституције тироидним хормонима на систолну и дијастолну функцију срца процењиван је ехокардиографским прегледом.

Резултати Двадесет пет (59,5%) испитаника је имало субклиничку, а 17 (40,5%) манифестну форму хипотиреоидизма. Ендсистолни дијаметар леве коморе се значајно смањио (p<0,01) после 12 недеља терапије, а енддијастолни дијаметар десне коморе после шест месеци терапије. Није било промена енддијастолног дијаметра леве коморе после шест месеци терапије тироидним хормонима. Вредности амплитуде систолне екскурзије равни митралног анулуса, ејекционе фракције леве коморе и амплитуде систолне екскурзије равни трикуспидног анулуса су статистички значајно повећане (p<0,01) после шест недеља терапије. Двадесет четири недеље после увођења тироидних хормона долази до статистички значајног смањења (p<0,01) концентрација укупног холестерола и ЛДЛ-Х, пораста ХДЛ-Х, а без утицаја на серумске концентрације триглицериде (p>0,05).

Закључак Супституционом терапијом тироидним хормонима код хипотиреоидних испитаника значајно су побољшани ехокардиографски параметри дијастолне и систолне функције леве и десне коморе, смањен је укупни холестерол и ЛДЛ-Х, а повећан ХДЛ-Х.

Кључне речи: хипотиреоза; Л-тироксин; дијастолна функција срца; систолна функција срца; липидни профил